Details of the Drug

General Information of Drug (ID: DMJYDVK)

Drug Name

Cariprazine

Synonyms

Cariprazine; 839712-12-8; RGH-188; RGH 188; Cariprazine(RGH188); UNII-F6RJL8B278; F6RJL8B278; CHEMBL3085826; 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea; Cariprazine [USAN:INN]; Reagila; MP-214; MP 214; Cariprazine (USAN/INN); Cariprazine (RGH-188); C21H32Cl2N4O; SCHEMBL184342; SCHEMBL184343; GTPL7671; SCHEMBL7861573; CHEMBL2028019; CHEBI:90933; HSDB 8310; DTXSID80232867; KPWSJANDNDDRMB-QAQDUYKDSA-N; MolPort-039-139-594; BDBM263449; BCP14691; BDBM50443101; BDBM50382290; ZINC38309313; 3526AH

Indication

Disease Entry	ICD 11	Status	REF
Bipolar disorder	6A60	Approved	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

427.4

Topological Polar Surface Area (xlogp)

4.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 1 week [3]
Metabolism: The drug is metabolized via the hydroxylation and demethylation [4]

Chemical Identifiers

Formula: C21H32Cl2N4O
IUPAC Name: 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
Canonical SMILES: CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl
InChI: InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)
InChIKey: KPWSJANDNDDRMB-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 11154555
ChEBI ID: CHEBI:90933
CAS Number: 839712-12-8
DrugBank ID: DB06016
TTD ID: D05XGO
INTEDE ID: DR0276
ACDINA ID: D00100

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Modulator	[2]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Bipolar disorder

ICD Disease Classification

6A60

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	2.50E-02	-0.08	-0.49
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cariprazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Cariprazine caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[41]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Cariprazine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[41]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Cariprazine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[42]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Cariprazine and Oliceridine.	Acute pain [MG31]	[43]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Cariprazine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[44]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Cariprazine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[44]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Cariprazine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[42]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Cariprazine caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[42]
Tucatinib	DMBESUA	Major	Decreased metabolism of Cariprazine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[42]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Cariprazine caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[41]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Cariprazine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[41]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Cariprazine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[41]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Cariprazine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[42]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Cariprazine and OPC-34712.	Depression [6A70-6A7Z]	[45]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Cariprazine and Esketamine.	Depression [6A70-6A7Z]	[46]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Cariprazine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Cariprazine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[41]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Cariprazine caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Cariprazine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[41]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Cariprazine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[42]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Cariprazine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[42]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Cariprazine caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[41]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Cariprazine and Levamlodipine.	Hypertension [BA00-BA04]	[47]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Cariprazine and TAK-491.	Hypertension [BA00-BA04]	[47]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Cariprazine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[45]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Cariprazine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[42]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Cariprazine caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[41]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Cariprazine and ITI-007.	Insomnia [7A00-7A0Z]	[45]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Cariprazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[48]
Ceritinib	DMB920Z	Major	Decreased metabolism of Cariprazine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[42]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Cariprazine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[42]
Idelalisib	DM602WT	Major	Decreased metabolism of Cariprazine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[42]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Cariprazine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[42]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Cariprazine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[41]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Cariprazine and Lasmiditan.	Migraine [8A80]	[49]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Cariprazine caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[41]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Cariprazine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[41]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Cariprazine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[50]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Cariprazine and Methylscopolamine.	Peptic ulcer [DA61]	[45]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Cariprazine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[51]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Cariprazine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[42]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Cariprazine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[42]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Cariprazine and Silodosin.	Prostate hyperplasia [GA90]	[47]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Cariprazine and Asenapine.	Schizophrenia [6A20]	[45]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Cariprazine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[42]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Cariprazine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[41]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Cariprazine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[41]
Armodafinil	DMGB035	Moderate	Increased metabolism of Cariprazine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[41]
LEE011	DMMX75K	Moderate	Decreased metabolism of Cariprazine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[42]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Cariprazine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[52]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Cariprazine caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[41]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Cariprazine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[45]
-----------


⏷ Show the Full List of 52 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Erythrosine sodium anhydrous	E00324	27872	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferric oxide black	E00522	16211978	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Colcothar yellow	E00436	518696	Colorant
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
Shellac	E00695	Not Available	Coating agent; Film/membrane-forming agent; Microencapsulating agent; Modified-release agent
--------------------


⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Cariprazine 3 mg capsule	3 mg	Oral Capsule	Oral
Cariprazine 4.5 mg capsule	4.5 mg	Oral Capsule	Oral
Cariprazine 6 mg capsule	6 mg	Oral Capsule	Oral
Cariprazine Hydrochloride eq 3mg base capsule	eq 3mg base	Capsule	Oral
Cariprazine Hydrochloride eq 6mg base capsule	eq 6mg base	Capsule	Oral
Cariprazine Hydrochloride eq 4.5mg base capsule	eq 4.5mg base	Capsule	Oral
Cariprazine Hydrochloride eq 1.5mg base capsule	eq 1.5mg base	Capsule	Oral
Cariprazine 1.5 mg capsule	1.5 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7671).
2	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206.
6	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
7	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
8	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
9	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
10	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
11	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
12	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
13	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
14	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
16	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
17	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
18	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
19	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
20	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
21	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
22	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
23	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
24	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
25	Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
26	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
27	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
28	Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
29	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
30	Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
31	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
32	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
33	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
34	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
35	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
36	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
37	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
38	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
39	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
40	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
41	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
42	Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
43	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
44	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
45	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
46	Cerner Multum, Inc. "Australian Product Information.".
47	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
48	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
49	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
50	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
51	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
52	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.